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The systemic uptake and local intestinal inflammatory potential of luminal bacterial cell wall polymers in rats
with normal and acutely inflamed colons were measured. Rats were injected intracecally with either
I251-labeled group A streptococcal peptidoglycan-polysaccharide complexes or equal amounts of Na'25 , after
either nonspecific colonic injury with 4% acetic acid or in'jection with buffer. The colons of rats injected with
peptidoglycan-polysaccharide had higher inflammatory scores than Na'"I-injected rats, a greater incidence of
mucosal ulceration and transmural inflammation after acetic acid injury, and an increased frequency of focal
accumulations of inflammatory cells in the lamina propria and submucosa after buffer injection. Radioactivity
in the liver, spleen, and mesenteric lymph nodes was higher in the colon-injured rats that received
peptidoglycan-polysaccharide 48 h before tissue colection than in the noninjured rats (P < 0.002). Group A
streptococcal polysaccharide antigen concentration within the liver, spleen, and mesenteric lymph nodes,
measured by enzyme-linked immunosorbent assay, was significantly higher in the colon-injured rats that
received cel waUl polymers than in noninjured rats. These results indicate that luminal bacterial cell wall
polymers with well-described inflammatory and immunoregulatory potential can cross injured colonic epithelia
and are capable of initiating and potentiating intestinal inflammation.
Bacterial cell wall polymers initiate and sustain acute and
chronic relapsing granulomatous inflammation with charac-
teristic immunological changes after local or systemic injec-
tion in laboratory animals (3, 33). Covalently bound pepti-
doglycan-polysaccharide complexes (PG-PS), the primary
structural component of cell walls of nearly all bacterial
species, including the normal intestinal flora, are responsible
for these inflammatory and immunomodulating effects.
Aqueous suspensions of purified group A streptococcal
PG-PS induce local granulomatous enterocolitis that persists
for 6 months when injected intramurally into rat intestines
(27) and chronic relapsing erosive synovitis (5), vasculitis
with skin lesions (4), uveitis (46), hepatic granulomas (40),
and anemia (R. B. Sartor, S. K. Anderle, W. J. Cromartie,
and J. H. Schwab, Abstr. Annu. Meet. Am. Soc. Microbiol.
1987, B146, p. 49) when injected systemically. In vivo and in
vitro immunomodulating effects of PG-PS include activation
of macrophages (30) and the classical and alternate comple-
ment pathways (8); mitogenic, adjuvant, and immunogenic
effects on B lymphocytes (18); and regulation of T cells (D.
Regan, P. Cohen, W. J. Cromartie, and J. H. Schwab,
submitted for publication). Because the histologic appear-
ance, systemic distribution of inflammation, and immuno-
logic changes induced by PG-PS resemble the inflammatory
characteristics of Crohn's disease and because high concen-
trations of bacteria and presumably their cell wall polymers
are found in the colon and distal small intestine, we have
postulated that PG-PS from intestinal bacteria is involved in
the pathogenesis of Crohn's disease; as well as certain other
chronic inflammatory diseases (5, 25). However, intestinal
PG-PS complexes must cross the epithelium if they are to
produce intestinal and systemic inflammation. High-molec-
ular-weight compounds within the intestinal lumen are capa-
ble of crossing the intestinal epithelium (19, 42), with evi-
dence of increased transport across injured intestines (28,
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36). In preliminary experiments we have demonstrated that
small but immunologically significant amounts of gavage-fed
group A streptococcal PG-PS are absorbed by the normal rat
intestine, as indicated by immunoreactive PG-PS within liver
and mesenteric lymph nodes and a serum immunoglobulin M
(IgM) response to PG-PS epitopes (26).
The goals of this study were to investigate systemic uptake
of luminal PG-PS across normal and nonspecifically injured
rat colons and to determine whether enteral PG-PS can
induce and perpetuate intestinal inflammation. Because
PG-PS is concentrated within macrophages in the liver,
spleen, and mesenteric lymph nodes after systemic injection
(7), we measured PG-PS radioactivity and antigen in these
organs after intracecal injection. In this paper we report that
mucosal absorption and systemic distribution of luminal
bacterial cell wall polymers are enhanced by acute colonic
injury. Furthermore, PG-PS induces mild mucosal and sub-
mucosal inflammation and potentiates nonspecific colonic
injury.
MATERIALS AND METHODS
Bacterial cell culture. Groilp A, type 3, strain D-58 strep-
tococci (Streptococcus pyogenes) were grown to early sta-
tionary phase in 15-liter batches of Todd-Hewitt broth (BBL
Microbiology Systems, Cockeysville, Md.) in a VirTis fer-
mentor (The VirTis Co., Gardiner, N.Y.) with continuous
stirring at 37°C. The pH was maintained at 7.00 to 7.03 by the
automatic addition of 5 N NaOH, and additional glucose was
added (1 liter of 45% glucose at 3 ml/min).
PG-PS purification. Bacterial cell wall fragments were
prepared as previously described (11). Briefly, bacteria were
washed three times with phosphate-buffered saline (PBS)
and broken by. shaking with glass beads in an MSK cell
homogenizer (Bronwill Scientific, Inc., Rochester, N.Y.).
Cell walls were separated from glass beads by filtration
through a coarse-sintered glass filter, the filtrate was centri-
fuged at 30,000 x g for 30 min, and the cell wall layer was
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washed three times in PBS. PG-PS polymers were then
prepared by extraction of the cell wall three times with 2%
sodium dodecyl sulfate (Sigma Chemical Co., St. Louis,
Mo.) at 56°C (10). PG-PS polymers were washed 10 times
with PBS and distilled water, dialyzed against distilled
water, and lyophilized. This entire procedure was carried
out under aseptic conditions, and the purified PG-PS prepa-
rations were sterile as determined by the lack of growth on
blood agar plates. PG-PS polymers ranging from molecular
weight (MW) 5 x 106 to 5 x 108 were prepared by sonication
for 45 min (Branson Sonicator) and removal of large frag-
ments by centrifugation at 1,000 x g for 30 min (11).
Rhamnose was measured colorimetrically by the method of
Dische and Shettles (6) and was the basis for determining
injection dose.
Radiolabeling of PG-PS fragments. Purified PG-PS frag-
ments were labeled with 1251 by a modification of the method
of Ulevitch (39) as previously described (10). Briefly, benzi-
midate-substituted PG-PS fragments were radiolabeled with
1251 using lactoperoxidase coupled to CNBr-activated Seph-
arose 4B (Pharmacia Fine Chemicals, Piscataway, N.J.) and
dialyzed against PBS to remove unbound 1251. Gel filtration
of the PG-PS suspension on Sephacryl S-200 (200,000 MW
exclusion limit; Pharmacia) demonstrated that the majority
of the 1251 was covalently bound to PG-PS, with a mean of
80% of radioactivity in the void volume and 4% in the
fractions corresponding to free 1251 on three determinations.
Each milliliter of 125I-PG-PS contained 5.4 x 107 cpm and
14.4 mg of cell wall as determined by rhamnose concentra-
tion.
Experimental protocol. Twenty female Sprague-Dawley
rats 7 to 9 weeks old (143 to 187 g) were obtained from
Zivic-Miller Laboratories, Allison Park, Pa. Rats were given
water containing 0.05 M Nal for 48 h prior to the experiment
and 0.5 ml of 0.15 M Nal via tail vein injection immediately
prior to laparotomy, in a modification of Skogh's technique,
to saturate their serum and tissue protein iodine-binding sites
(29). In a preliminary experiment, oral and intravenous Nal
pretreatment of rats gavage-fed 1251 decreased tissue and
blood radioactivity by 74.5 to 93.5% (data not shown). Rats
were divided into four groups of five rats each and fasted
overnight. Animals were anesthetized with an intramuscular
injection of 0.13 ml of Innovar (fentanyl, 0.05 mg, plus
droperidol, 2.5 mg/ml; Janssen Pharmaceutica, Inc., Piscat-
away, N.J.) per 100 g of body weight and given 0.5 ml of 0. 15
M Nal via tail vein injection. After a laparotomy under
aseptic conditions, a ligature of 4-0 silk was placed at the
cecal-ascending colon junction. Using a modification of the
method of Krawisz et al. (15), colon injury was produced in
groups I and II by injecting 1.5 ml of 4% acetic acid (HAc)
into the ascending colon approximately 5 mm distal to the
suture, followed at 20-s intervals by injections of 2 ml of air
and 3 ml of PBS at the same site. Rats in groups III and IV
(noninjured colon groups) received injection of 1.5 ml of PBS
into the ascending colon followed at 20-s intervals by 2 ml of
air and 3 ml of PBS. Immediately after the ascending colon
injections, rats in groups I and III then were injected with 1
ml of radiolabeled PG-PS (5.4 x i07 cpm) into the superior
portion of the cecum, while groups II and IV received
intracecal injections of 1 ml of Na125I (5.4 x 107 cpm). All
injections were done with 27-gauge needles. Preliminary
studies demonstrated that 1251 levels within luminal contents
of the distal ileum and proximal jejunum were not different 2
and 4 h after injection, indicating that 1251 injected into the
cecum did not reflux into the small intestine. The ligature
around the cecal-ascending colon junction was then re-
moved, and the abdominal incision was closed with two
layers of 4-0 chromic and 4-0 silk sutures. Each group of rats
was then placed in separate cages with food and water ad
libitum. Forty-eight h after injection, rats were killed with
carbon dioxide, their intestines were examined grossly, and
tissues were collected for histology, radioactive counting,
and immunoassay. Portions of the liver, spleen, mesenteric
lymph nodes, cardiac blood, cecal contents, and an ankle
joint with skin removed were weighed, and the amount of
1251 was determined with a gamma counter (1197 series,
automatic Gamma Counting System; Searle Analytic Inc.,
Des Plains, Ill.). After counting, tissues for immunoassay
were stored at -20°C in sterile tubes and the intestines were
fixed in 10% buffered Formalin. Forty-eight h was used as
the experimental time point because preliminary studies
showed reproducible inflammation with 4% HAc and less
retention of free 1251 within organs than at earlier time points.
Immunoassay. Preparation of liver, spleen, and mesenteric
nodes for enzyme-linked immunosorbent assay (ELISA) of
group A streptococcal polysaccharide was carried out in the
following manner. Weighed specimens were homogenized in
a glass tissue grinder with 0.6 ml of 0.1 M Tris with 1%
Tween 80 and 0.02% sodium azide per g of tissue. Each
sample was then sonicated for 10 min (Raytheon Sonicator)
and centrifuged at 13,000 x g for 5 min. Radioactivity of
supernatants was compared with values before homogeniza-
tion to correct for loss of antigen during the homogenization
and centrifugation steps. The supernatant contained 46%
(mean value of eight tissues; range, 35.7 to 67.3%) of the
radioactivity that was present within the tissue prior to
homogenization and measured 0.73 ml for 1 g of tissue. The
extraction efficiency was similar in the liver, spleen, and
mesenteric lymph nodes. The amount of PG-PS in the
supernatant was measured by the microELISA method
developed by Eisenberg et al. (1, 7). Extracts of tissues were
added to 96-well microtiter plates previously coated with
rabbit anti-group A streptococcal polysaccharide antibody (1
,ug/ml) which had been affinity purified on an N-acetylgluco-
samine column. Biotinylated affinity-purified anti-group A
polysaccharide antibody (1 jig/ml) was then added, followed
by avidin-conjugated alkaline phosphatase. The color reac-
tion was developed with p-nitrophenylphosphate substrate
and read in an automated microELISA reader (Dynatech
Laboratories, Inc., Alexandria, Va.). A standard curve was
constructed using known amounts of PG-PS. The concentra-
tion of PG-PS within whole organs was calculated using the
formula: tissue weight (g) x 0.73 mlI/g x value (pg/ml),
divided by 46% to correct for extraction losses. The validity
of this method of measuring PG-PS within tissues was
substantiated by measuring known concentrations of PG-PS
added to normal liver extracts. There was no evidence of
significant tissue inhibitors, and measurement of PG-PS
correlated well with added amounts.
Histologic scoring criteria. A section of the proximal,
middle, and distal colon was obtained from each rat after
fixation in 10% buffered Formalin. Sections were collected
from grossly involved tissues, if present, or 1 cm distal to the
injection site and from the mid-transverse and mid-de-
scending colon in grossly normal specimens. Tissues were
embedded in paraffin, and sections were stained with hema-
toxylin and eosin and then scored in a blinded fashion by a
single observer (R.B.S.) on a 0 to 4+ scale as follows: 0,
normal tissue; 1+, increased mononuclear cells or presence
of scattered polymorphonuclear leukocytes (PMNs) with no
thickening of the lamina propria or submucosa; 2+, moder-
ate increase in inflammatory cells with some thickening of
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FIG. 1. Histology of acute inflammation of a rat colon injected with 4% HAc and 14.4 mg of sonicated group A streptococcal PG-PS 48
h before harvesting (group I). The mucosa is focally inflamed with denuded epithelium, shallow ulcers, and infiltration of the lamina propria
with PMNs adjacent to intact mucosa with limited inflammation. The submucosa is thickened with infiltrating PMNs. (Hematoxylin plus eosin
stain.)
the intestinal wall; 3+, marked increase in PMNs or mono-
nuclear cells or both, widening of the lamina propria or
submucosa, and focal mucosal ulcers; 4+, widespread ulcer-
ation and necrosis. The percentage of the surface area that
was denuded of epithelial cells and the presence of trans-
mural inflammation and PMNs were noted on each section of
intestine.
Statistical evaluation. The mean and standard error of the
mean for inflammatory scores, percentage of mucosal sur-
face ulcerated, tissue radioactivity, and antigen concentra-
tions were computed for each group. Results were analyzed
to determine whether the data were parametric or nonpara-
metric. Most results were nonparametric. Statistical signifi-
cance of HAc and PG-PS exposure was determined by
parametric or nonparametric analysis of variance. If this
analysis indicated a statistical difference, the individual
groups were further compared using parametric or nonpara-
metric one-tailed T tests, as appropriate. Alpha levels were
adjusted on the basis of the number of comparisons made.
RESULTS
Clinical observations. All rats which had 4% HAc injected
into the colon developed signs of systemic illness by 12 to 24
h after gut injury. This included both group I (HAc + PG-PS)
and group II (HAc + Na125I). Most prominent signs included
decreased activity level and watery diarrhea. Several ani-
mals developed mild conjunctivitis. In contrast, rats in
groups III (PBS + PG-PS) and IV (PBS + Na1251), which did
not receive colonic injection of HAc, showed no evidence of
illness and had completely recovered from surgery by 12 h
after laparotomy.
Gross observations. All rats with HAc colon injury (groups
I and II) had hemorrhages on the serosal (external) surface of
the ascending colon near the injection site and on focal areas
of the transverse and descending colon and rectum. The
mucosal surface of the HAc-injured colons contained exten-
sive areas of sharply demarcated ulceration with an adherent
grey or tan exudate and hemorrhage. Mucosal ulceration
was consistently present in the proximal colon near the
injection site and in the mid-colon, but was less evident in
the distal colon. The cecum and small intestines were grossly
normal. In contrast, control rats injected with PBS (groups
III and IV) had no grossly visible abnormalities of the serosal
or mucosal surfaces of the colon.
Microscopic observations. All animals with HAc injury had
obvious colonic injury. There were multiple areas of hemor-
rhagic necrosis of the mucosa with marked thickening of the
lamina propria and dense infiltration of PMNs. Areas of
intense inflammation with ulceration were adjacent to areas
with intact epithelium but increased numbers ofPMNs in the
submucosa (Fig. 1). Inflammation was present from the
injection site in the ascending colon to the distal colon,
although the descending colon was less actively involved.
Group I (HAc + PG-PS) colon sections had higher inflam-
matory scores, and a larger percentage of the colonic surface
area was denuded of epithelial cells, than was the case for
group II (HAc + Nal25I) (Table 1). Transmural inflammation
and PMNs were more frequently seen in sections from group
I than other groups. PBS-injected colons had no evidence of
mucosal ulceration or transmural inflammation (Fig. 2).
However, 73% of the sections from group III (PBS + PG-PS)
had increased numbers of mucosal and submucosal mono-
nuclear cells as compared with 27% of group IV (PBS +
Na1251) sections, and the inflammatory score of group III
was higher than that of group IV (P = 0.003). One rat in
group III had submucosal PMNs (Fig. 3) associated with a
2+ inflammatory score. These blindly read results suggest
that PG-PS within the colonic lumen potentiated HAc-
induced injury and produced mild inflammation in buffer-
injected animals.
Systemic uptake from the colon and tissue distribution of
PG-PS. The radioactivity levels of livers, spleens, and mes-
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TABLE 1. Histological evaluation of colonic inflammation
Mean Mean % of T I Mucosal and
Group inflammatory surface Trnmba PMNs ()submucosalGroupscore' ± SE denuded' ± SE inflammationb (%) inflammationb (%)
Group I (HAc + PG-PS) 3.6 ± 0.1l 66.7 ± 3.8d 16/18c (89) 18/18c (100) 18/18C (100)
Group II (HAc + 1251) 3.0 ± 0.4 45.7 ± 4.7 10/15 (67) 13/15 (87) 13/15 (87)
Group III (PBS + PG-PS) 0.9 ± 0.2e 0 0/15 (0) 1/15 (7) 11/15 (73)e
Group IV (PBS + 1251) 0.3 ± 0.1 0 0/15 (0) 0/15 (0) 4/15 (27)
a Results are obtained from microscopic evaluation of three colonic sections from each rat, five rats in each group (except group I, n = 6).
b Number of colonic sections positive/total number of sections examined, percentage in parentheses.
c p 0.06 compared with group II.
dp = 0.02 compared with group II.
e p 0.009 compared with group IV.
enteric lymph nodes were higher in group I (HAc + PG-PS)
than in all other groups for each tissue measured (Table 2).
Although organ radioactivity in group III (PBS + PG-PS)
was much lower than in the colon-injured groups, levels
were significantly higher (P c 0.003) than those of group IV
(PBS + Na1251), suggesting transport of radiolabeled PG-PS
across noninjured colon. Radioactivity of cecal contents 48 h
after injection was much higher in the rats receiving PG-PS
than in those receiving Na125I for both HAc-injured groups
(group I, 689 x 103 cpm/g, versus group II, 22 x 103 cpm/g;
P < 0.001) and noninjured groups (group III, 19 x 103 cpm/
g, versus group IV, 0.8 x 103 cpm/g; P = 0.003). These
results indicate a higher rate of absorption or emptying of
free 1251 from the cecum compared with the higher-MW
PG-PS and also suggest that colonic injury with HAc delays
cecal emptying. Organs ofgroup I animals also contained the
highest percentage uptake of injected radioactivity, and
group III levels were significantly higher than those of group
IV (P < 0.001) (Table 2).
To determine whether radioactivity within tissues repre-
sented radiolabeled PG-PS or merely enzymatically cleaved
free 1251, immunoreactive group A streptococcal PG-PS was
measured in liver, spleen, and mesenteric lymph node ho-
mogenates by ELISA (Fig. 4). Group I (HAc + PG-PS) had
significantly higher levels of PG-PS in all tissues than did
group III (PBS + PG-PS). Group III (PBS + PG-PS) did not
have higher levels of immunoreactive PG-PS than control
tissues. Positive values for control tissue homogenates prob-
ably represent cross-reactivity of endogenous PG-PS or
tissue antigens with the group A streptococcal polysaccha-
ride epitope. The data in Table 3 demonstrate that the
colon-injured rats that received PG-PS (group I) had a higher
percentage of injected cell wall within their organs than did
noninjured rats (group III).
DISCUSSION
The implications of transport of macromolecules across
the normal and injured intestine have been discussed in
several reviews (23, 41, 42). However, uptake of intestinal
PG-PS complexes across colonic epithelium, a process of
potential importance in inducing and maintaining intestinal
and systemic inflammation, has not been previously shown.
Our results indicate that small but detectable amounts of
luminal group A streptococcal PG-PS were transported into
the liver, spleen, and mesenteric lymph nodes of rats whose
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FIG. 2. Photomicrograph of a control rat's colon injected with PBS and Na'251 48 h before tissue collection (group IV). No significant
inflammation is apparent. (Hematoxylin plus eosin stain.)
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FIG. 3. Inflammation of a rat colon injected with PBS and intracecal sonicated group A streptococcal PG-PS polymers 48 h before tissue
collection (group III). Acute and chronic inflammatory cells infiltrate the thickened submucosa, and a focal accumulation of lymphocytes is
present in the lamina propria (arrow). (Hematoxylin plus eosin stain.)
colons were nonspecifically injured with 4% HAc. In a
preliminary study we found that gavage-fed group A strep-
tococcal PG-PS was detected within systemic organs of
normal rats with noninjured intestines and that rats fed
PG-PS had increased serum IgM antibodies to PG (26). In
the present study, in which radiolabeled PG-PS was injected
into the cecum, both tissue immunoassay and radiolabel
results demonstrated enhanced transport of PG-PS across
the acutely injured colon, but very little systemic uptake of
PG-PS across the noninflamed colon. Presumably, after
PG-PS is fed, most of the antigen is absorbed in the small
intestine. These results are in agreement with those of
Warshaw et al., who demonstrated that colonic absorption
of 3H-labeled bovine serum albumin was much less than
small intestinal absorption: 0.13% versus 1.7% of the admin-
istered dose, respectively (43). It is probable that in the
noninjured state, absorption of PG-PS is more efficient in the
small intestine than in the colon because of increased surface
area or increased permeability (or both) of the small intesti-
nal epithelial cells. However, the concentration of indige-
nous bacteria and, presumably, soluble PG-PS is higher in
the colon than in the proximal small bowel by a factor of at
least 106.
The radioisotope method of measuring PG-PS transport
produced a higher percentage of uptake of administered cell
wall than the immunoassay method. This discrepancy prob-
ably reflects an overestimation of uptake due to luminal
cleavage of the '25I-PG-PS complex, with subsequent muco-
sal absorption of free 125I (16, 37) and binding of 1251 (29) or
partially degraded radiolabeled fragments (38) to serum and
tissue proteins. We took the following measures to minimize
and control for absorption and tissue binding of free 125I. (i)
The radiolabeled PG-PS injected into rats was extensively
dialyzed to remove unbound 1251 and was shown to have
very little free 125I by column chromatography. (ii) We
minimized nonspecific binding of absorbed free 1251 to tissue,
serum, and luminal proteins by saturation with oral and
intravenous NaI before injection of radiolabeled PG-PS (29).
(iii) Control rats were injected with equal amounts of Na1251
to control for the maximum possible unlabeled 1251 transport
and tissue binding. In spite of these precautions, some of the
radioactivity measured within the tissues probably repre-
TABLE 2. Tissue distribution of 251I-labeled PG-PS after injectiona
cpm (103)/organ": % (10-2) of injected cpm in organb:
Group Mesenteric Mesenteric
Liver Spleen lymph nodes Liver Spleen lymph nodes
Group I (HAc + PG-PS) 359 ± 103c 21.4 5.6d 29.3 ± 9.5d 67 ± 19d 4.0 ± 1.0d 5.4 ± 1.7d
Group II (HAc + Na125I) 213 ± 43 13.1 ± 3.0 13.9 ± 4.0 39 ± 8 2.5 ± 0.6 2.6 ± 0.8
Group III (PBS + PG-PS) 26 ± 8 1.4 ± 0.2 1.3 ± 0.3 5 ± 1 0.3 ± 0.2 0.24 ± 0.06
Group IV (PBS + NA1251) 5 + 1c 0.3 ± 0.04d 0.3 ± 0.02d 1 ± 0.3d 0.04 ± 0.02d 0.06 ± 0.004d
a Groups I and II were injected with 4% NAc into the ascending colon and "25I-labeled PG-PS (5.4 x 107 cpm, 14.4 mg) or Na125I (5.4 x 107 cpm) into the cecum
48 h before harvesting. Groups III and IV were injected with PBS into the ascending colon, and then the same doses of '25I-labeled PG-PS or Na1251 as for groups
I and II were injected into the cecum.
b Mean ± standard error of the mean.
c P c 0.003 versus group III.
d p _ 0.001 versus group III.
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FIG. 4. Measurement of systemically absorbed group A strepto-
coccal PG-PS antigen within organs. PG-PS was measured by
ELISA using affinity-purified antibody to group A streptococcal
polysaccharide in tissues of rats with and without colonic injury with
4% HAc and injected intracecally with PG-PS (14.4 mg) or Nal25I. *,
P = 0.002 compared with group I; **, P = 0.03 compared with group
I. Hatched bars, Group I (HAc + PG-PS); stippled bars, group II
(HAc + 1251); open bars, group III (PBS + PG-PS); solid bars, group
IV (PBS + 1251). Mesenteric LN, Mesenteric lymph nodes.
sents free 1251 cleaved from PG-PS by pancreatic, mucosal
brush border, and bacterial enzymes within the intestinal
lumen (37). Unlabeled PG-PS of group A streptococci is
resistant to proteolysis by trypsin (3). Alternative reasons
for the lower levels of antigen relative to radioactivity within
tissues are that the N-acetyl-D-glucosamine epitope of
PG-PS measured in the ELISA could have been cleaved by
intestinal N-acetylglucosamidase (35) derived from luminal
bacteria and mucosal lysosomes or that PG-PS antigen was
poorly extracted from tissues. Measurement of 1251 was
performed on whole organs, while the immunoassay was
performed on supematants of homogenized organs. There-
fore, the immunoassay may have understated the true
amount of PG-PS within tissues. However, both the radio-
labeling and ELISA techniques demonstrate clearly that
nonspecific mucosal injury with HAc enhances systemic
uptake of luminal PG-PS.
Luminal macromolecules are absorbed in small amounts
by the normal intestine, while increased absorption of high-
MW compounds follows gut injury. Small amounts of horse-
radish peroxidase (MW 40,000) and intact bovine serum
albumin (MW 68,000) are transported by small intestinal
epithelial cells into the portal vein and intestinal lymphatics
(44). Owen et al. have demonstrated that particles ranging in
size from horseradish peroxidase (19) to intact bacteria (21)
and Giardia muris (20) are transported by specialized epi-
TABLE 3. Tissue distribution of colon-injected PG-PS
by ELISAa
% (10-) injected PG-PS'
Group Mesenteric
Liver Spleen lymph nodes
I (HAc + PG-PS) 16 ± 2c 1.6 ± 0.3 0.60 + 0.12
III (PBS + PG-PS) 11 + 1 1.5 + 0.3 0.38 + 0.05
a See Table 2 footnotes.
b Mean ± standard error of the mean.
c P = 0.03 compared with group III.
thelial cells (M cells) to adjacent macrophages within Peyer's
patches of normal laboratory rodents. Talbot et al. (36)
showed enhanced uptake of horseradish peroxidase into the
portal blood of guinea pigs whose small intestines were
perfused with 0.05 to 0.2% lysolecithin and 5% ethanol in the
absence of morphological evidence of mucosal damage,
while Worthington and Syrotuck demonstrated ferritin (MW
650,000) and adenovirus type 5 (MW <1,000,000) in the
lamina propria and between epithelial cells of rats kept on a
low-protein diet for 4 months (47). Seidman et al. (28) have
shown increased recovery of rectally administered polyeth-
ylene glycol (MW 4,000) from the urine of rabbits with
immune complex-mediated colitis. Crohn's disease patients
and their clinically unaffected relatives had increased ab-
sorption of polyethylene glycol (average MW of 400), which
suggests a primary defect of barrier function in this disorder
(13). Our observations confirm that experimental colitis
enhances the systemic transport of luminal macromolecules,
and they extend the previous studies by investigating the
absorption of biologically active compounds rather than
inert markers serving only as indicators of transport.
These results are plausible, based on the considerable
evidence that luminal bacteria and bacterial antigens can
cross the intestinal epithelium. We have documented nor-
malization of the cell-mediated immune response of germ-
free mice fed PG-PS (C. J. Woolverton et al., Gastroenter-
ology, 94:A503, 1988), a rise in serum IgM antibodies to
peptidoglycan in normal rats gavage-fed PG-PS (26), and
increased levels of serum IgA and IgM to peptidoglycan in
Crohn's disease patients as compared with patients with
other gastrointestinal disorders and normal controls (R. B.
Sartor et al., Gastroenterology, 88:1571, 1985). Crohn's
disease patients have increased serum antibodies to a variety
of indigenous bacterial species (24, 34), indicating increased
absorption of, or enhanced immunoresponsiveness to, bac-
terial antigens. Park et al. (22) suggested that soluble pepti-
doglycan in the urine of normal human volunteers treated
with oral penicillin was derived from the intestinal bacteria;
however, they could not exclude the possibility of vaginal
bacterial contamination. There is indirect evidence of intes-
tinal lipopolysaccharide (endotoxin; MW >300,000) absorp-
tion in mice (12) and detection of plasma lipopolysaccharide
in 17 of 18 Crohn's disease patients in a recent trial of
intestinal lavage (45). Berg and co-workers have recovered
viable normal enteric flora bacteria from the mesenteric
lymph nodes, livers, and spleens of rodents under a variety
of experimental conditions, including administration of rici-
noleic acid in concentrations approximating therapeutic
doses of castor oil (17). Thus it is logical to assume that
PG-PS polymers with an MW of 5 x 106 to 5 x 108 could be
transported across ulcerated colonic mucosa, particularly if
the polymers are partially degraded by luminal enzymes.
Sufficient absorption of intestinal PG-PS in an immunolog-
ically active form could have profound local and systemic
inflammatory and immunological consequences. Aqueous
suspensions of group A streptococcal PG-PS produce
chronic, spontaneously relapsing granulomatous inflamma-
tion leading to fibrosis in a variety of tissues in laboratory
animals (3, 33), including the intestine after intramural
injection (27). Associated with the inflammatory reactions in
these animal models is a characteristic chronic immunologic
response (33). In the present study PG-PS injected into the
cecum potentiated injury induced by HAc and produced
focal increases of mucosal and submucosal inflammatory
cells in noninjured rats. We used group A streptococcal
PG-PS because of its resistence to in vivo degradation (7)
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and because our ELISA could distinguish it from rat normal
flora bacterial antigen within tissues. It is important to note
that PG-PS polymers occur in nearly all gram-positive bac-
terial species and that PG-PS from bacteria found within
normal rodent and human intestines also has the ability to
produce protracted inflammation. We have produced
chronic granulomatous enterocolitis persisting at least 8
weeks with the intramural injection of Streptococcus fae-
cium (group D Streptococcus) PG-PS (27). Stimpson et al.
(31) induced arthritis in rats by intraperitoneal injection of
sonicated PG-PS derived from two strains of S. faecium and
Peptostreptococcus productus, a gram-positive anaerobe
which is 1 of the 10 most commonly isolated bacterial
species from human feces. The recent observations that
systemically injected lipopolysaccharide can reactivate PG-
PS-induced arthritis (10, 32) and that formylated peptides
(formylmethionyl-leucyl-phenylalanine [FMLP] and formyl-
norleucyl-leucyl-phenylalanine [FNLP]) can produce acute
colitis (2) are important because it is likely that many luminal
bacterial products, including PG-PS, lipopolysaccharide,
and FMLP, are absorbed concurrently after gut injury. In
addition to their inflammatory role, enhanced local and
systemic absorption of bacterial products could produce
many of the immunological changes associated with intesti-
nal inflammation (9, 14). Although the amount of PG-PS
transported across the normal and inflamed intestine is
small, accumulation of these poorly degradable polymers
within tissues could be sufficient to produce protracted
intestinal and systemic inflammation and immunologic alter-
ations in the genetically predisposed host, for example,
inflammatory bowel disease or reactive arthritis patients. We
postulate that transport of luminal PG-PS derived from
normal enteric bacteria induces or perpetuates the intestinal
and extraintestinal inflammation of Crohn's disease and
ulcerative colitis.
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